The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guideline update on the management of dyslipidemia continues to focus largely on how best to manage lipid levels to reduce cardiovascular (CV) risk. Although some things have remained the same, some important new recommendations have been added, based on evidence from several clinical trials published from 2019 onwards.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Obesity: A Multimodal and Interdisciplinary Approach
New Swiss Clinical Practice Guideline Provides Guidance
- cSCC: Personalizing Treatment Strategies and Follow-up Care Plans
Comprehensive risk stratification is no simple matter: what’s new?
- Baxdrostat – a new class of drugs for treating difficult-to-control hypertension
First Aldosterone Synthase Inhibitor Is Here
- Geriatric Small-Cell Lung Cancer
Therapeutic Challenges
- Chronic Pruritus in Renal, Hepatic, and Biliary Tract Diseases
Pooled Expertise for Targeted Evaluation and Treatment
- Advanced Thyroid Cancer
Molecular Mechanisms and New Therapeutic Approaches
- Epidermolysis bullosa
Promoting Wound Healing with Gene Therapies and Birch Bark Extract
- From Risk Identification to Anti-Inflammatory Intervention